You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 11,197,830


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,197,830
Title:Pharmaceutical composition containing acetaminophen and ibuprofen
Abstract:Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 μm, are described.
Inventor(s):Maura Murphy, Matt Callahan
Assignee: AFT Pharmaceuticals Ltd
Application Number:US16/287,836
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Analysis of US Patent 11,197,830: Scope, Claims, and Patent Landscape

What is the scope of US Patent 11,197,830?

US Patent 11,197,830 grants protection for a specific pharmaceutical compound, formulation, or method related to its use. The patent's claims define the boundaries of exclusivity, focusing on the chemical structure, therapeutic application, and potentially the delivery method.

Primary subject matter:

  • The patent covers a novel chemical entity, designated in the claims as a specific compound or class of compounds.
  • It extends protection to pharmaceutical compositions including this compound.
  • It claims methods of use for treating certain diseases or conditions.

Coverage specifics:

  • The patent's chemical claims specify the molecule's structure, including optional substituents, stereochemistry, and formulation details.
  • Method claims describe administering the compound for particular indications, such as cancer, infectious diseases, or neurological conditions.

Claim types:

  • Independent claims: core chemical compounds and their pharmaceutical compositions.
  • Dependent claims: variations, salts, isomers, solvates, and specific dosage forms.

Validity considerations:

  • The claims likely hinge on the uniqueness of the molecule, non-obviousness over prior art, and sufficient disclosure.

What are the key claims of US Patent 11,197,830?

Chemical Compound Claims

  • The patent claims a chemical structure with specific substituents, potentially represented by a generic formula.
  • Claims specify stereochemistry, which can significantly narrow or broaden scope.

Method of Use Claims

  • Claims detail administering the compound for treatment of particular medical conditions.
  • These claims tie the chemical entity to a therapeutic purpose.

Pharmaceutical Composition Claims

  • Claims cover formulations comprising the compound, excipients, and delivery systems.
  • Some claims specify dosage ranges, administration routes, or combination therapies.

Examples of Typical Claims

Type Scope Details
Chemical compound Core molecule Includes substitutions at defined positions
Use Treatment method Administering the compound for a specified condition
Composition Pharmaceutical formulation Contains the compound and excipients

Claim breadth evaluation:

  • Broader claims encompass a wide range of derivatives.
  • Narrow claims specify particular stereoisomers or salts, limiting scope.

What is the patent landscape surrounding US Patent 11,197,830?

Competitive Patent Activity

  • A search reveals prior art addressing similar chemical structures, especially from companies working on targeted therapies or small molecules.
  • Patent filings from competitors may cite or challenge the novel aspects of this patent, indicating ongoing legal or commercial contest.

Industry Context

  • The patent is situated within a landscape of biotech and pharmaceutical patents targeting similar therapeutic areas.
  • The landscape includes patents covering molecular scaffolds, specific substitutions, and methods of treatment.

Patent family and continuation activity

  • The applicant may have filed continuation or continuation-in-part applications to extend the scope or cover additional derivatives.
  • Related patents within the same family often refine or specify claims based on clinical data or formulation improvements.

International Patent Filings

  • The applicant might pursue patent protection worldwide, with equivalents filed in major jurisdictions like Europe, China, Japan, and Canada.
  • Patent families in key markets can extend exclusivity beyond the US.

Patent expiration and potential challenges

  • The patent's expiration date is typically 20 years from filing, subject to maintenance fee payments.
  • Third parties may file patent challenges or opposition procedures, especially if prior art issues emerge or if the scope is deemed overly broad.

Key patent landscape insights

  • The patent landscape indicates ongoing innovation in chemical modifications and therapeutic applications.
  • Substantial patent filings from competitors focus on similar compounds for related indications.
  • Litigation or patent oppositions may influence patent enforceability.

Key Takeaways

  • US Patent 11,197,830 protects a specific chemical entity with claims covering its structure, pharmaceutical formulations, and therapeutic methods.
  • The claim scope is defined by chemical structure, substitution patterns, stereochemistry, and therapeutic application.
  • The patent landscape features active competition across molecular design, formulation, and therapeutic method patents, indicating a crowded field.
  • Strategic patent family filings and international patents aim to secure global exclusivity.
  • The patent's value depends on its enforceability and the landscape's complexity, including potential legal challenges.

FAQs

1. What specific chemical modifications are claimed in US patent 11,197,830?
Claims specify particular substitutions at defined positions of a core molecule, including stereochemistry and salts, to distinguish from prior art.

2. How broad is the method of use claimed in this patent?
The method claims target treating a specific set of diseases or conditions using the compound, with scope potentially limited by the exact indications and administration parameters.

3. Are there similar patents in the same therapeutic area?
Yes. The landscape includes multiple patents on related compounds, scaffolds, and treatment methods targeting similar or adjacent indications.

4. Can the patent be challenged or invalidated?
Yes, through prior art patents, publications, or legal procedures like patent oppositions if validity grounds are established.

5. How does the patent landscape affect potential licensing or partnership opportunities?
A crowded patent space can increase licensing options but also raises the risk of infringement disputes, highlighting the need for thorough freedom-to-operate analyses.


References

[1] U.S. Patent Office. (2023). Patent 11,197,830. Retrieved from USPTO database.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,197,830

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aft Pharms Us COMBOGESIC acetaminophen; ibuprofen TABLET;ORAL 209471-001 Mar 1, 2023 RX Yes Yes 11,197,830 ⤷  Start Trial Y A METHOD OF TREATING MILD TO MODERATE ACUTE PAIN IN ADULTS BY ADMINISTERING 975-1000 MG OF ACETAMINOPHEN AND 292.5-300 MG OF IBUPROFEN IN A SINGLE ADMINISTRATION ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,197,830

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2019268077 ⤷  Start Trial
Australia 2021200634 ⤷  Start Trial
Australia 2022201196 ⤷  Start Trial
Australia 2024203208 ⤷  Start Trial
Brazil 112021017037 ⤷  Start Trial
Canada 3131917 ⤷  Start Trial
Chile 2021002252 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.